Foghorn Therapeutics (FHTX) Operating Leases (2019 - 2026)

Foghorn Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $40.1 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 55.92% year-over-year to $40.1 million in Q1 2026; TTM through Mar 2026 was $40.1 million, a 55.92% increase from a year earlier, with the FY2025 full-year figure at $40.3 million, up 43.77% from the prior year.
• Operating Leases retreated to $40.1 million in Q1 2026 per FHTX's latest filing, from $40.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $51.5 million in Q4 2022 and bottomed at $15.8 million in Q3 2025.
• The 5-year median for Operating Leases is $40.1 million (2026), against an average of $37.2 million.
• Across the five-year window, Operating Leases sank 47.94% in 2025 and soared 55.92% in 2026, its largest moves.
• Year by year, Operating Leases stood at $51.5 million in 2022, then declined by 12.49% to $45.1 million in 2023, then slumped by 37.74% to $28.1 million in 2024, then soared by 43.77% to $40.3 million in 2025, then decreased by 0.54% to $40.1 million in 2026.
• Per Business Quant, the three latest FHTX Operating Leases figures stand at $40.1 million (Q1 2026), $40.3 million (Q4 2025), and $15.8 million (Q3 2025).